CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.
This affirmation of AdaptHealth’s ratings indicates Moody’s expectation that the company will continue its modest organic growth, particularly in the diabetes segment, following improved operating ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback